Shots:
- GSK will make equity investment to gain access to Vir’s technology of $250M, priced at $37.73 (a 10% premium to closing share price on March 27, 2020). The equity investment and collaboration will complete at the same time & are conditional upon customary conditions including regulatory review by appropriate regulatory agencies under Hart-Scott-Rodino Act
- The collaboration will focus on development of specific antibody candidates identified by Vir’s platforms (VIR-7831 and VIR-7832) which demonstrated high affinity for SARS-CoV-2 spike protein and highly potent in neutralising SARS-CoV-2 in live virus-cellular assays. The companies plan to proceed directly into P-II clinical trial within next 3 to 5 mos.
- Vir’s antibody platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in the Democratic Republic of Congo), hepatitis B virus, influenza A, SARS-CoV-2, malaria, and others
Click here to read full press release/ article | Ref: GSK | Image: BGR
The post GSK Signs an Agreement with Vir Biotechnology to Develop Solutions for Coronaviruses first appeared on PharmaShots.
